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Regenerative stem cell research is now rapidly moving toward
the clinic and routine medical applications. With the number
of Phase II and III trials growing, the conduct of multi-country
clinical research collaborations is becoming increasingly im-
portant. These partnerships accelerate processes of clinical
translation, and form the basis for marketing approval of new
therapies in multiple countries (Martell et al., 2010). At
present, however, the conduct of international stem cell trials
is hampered by a high level of regulatory heterogeneity across
countries, and the absence of internationally harmonized
governance frameworks (Bubela et al., 2014). Even though
drug regulatory authorities in the USA, the European Union
and Canada have now initiated collaborations that focus on
the convergence of regulatory procedures for cellular therapy
products, globally harmonized regulatory procedures are far-
off (Arcidiacono et al., 2012). Japan for instance, has recently
introduced a fast-track approval path for stem cell therapies
(Cyranoski, 2013), and in China and India drug regulatory
agencies have at present only issued provisional regulations
and regulatory guidelines whose legal power is limited
(Sleeboom-Faulkner and Patra, 2011; Viswanathan et al.,
2013; Rosemann, 2013). But complications arise also from
the ongoing growth of unregulated stem cell treatments
that are offered to patients without systematic proof of
safety and efficacy in many countries (Lysaght and Sipp, 2014;
Ogbogu et al., 2013). Lucrative business opportunities and the
existence of regulatory grey areas have given rise toE-mail address: ar253@sussex.ac.uk.
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(http://creativecommons.org/licenses/by/4.0/).uncontrolled applications and the emergence of transnation-
al entrepreneurial networks that advocate alternative
forms of research regulation. Professional associations
such as the International Cellular Medicine Society (ICMS),
for example, have developed their own guidelines and IRB
and accreditation services (Blasimme, 2013). These activ-
ities support experimental for-profit interventions with
stem cells outside of the methodological format of the
randomized controlled trial and independent from the
review procedures of drug regulatory agencies (Rosemann,
under review). This diversification of clinical research
standards within and across countries makes efforts of
international harmonization increasingly difficult.
In Part I of this paper I will introduce four central challenges
to the organization of international stem cell trials that
emerge from this high level of regulatory variation. These
obstacles apply in principle to all innovative multi-country
stem cell trials that are subject to approval by a drug
regulatory authority, including trials with (minimally manipu-
lated) autologous stem cells. These challenges are especially
pronounced, however, in the case of trials with pluripotent
stem cells that involve increased technical complexity and
higher risks for patients. Exceptions are trials that involve
established stem cell treatments (such as the use of hemato-
poietic stem cells for leukemia), or studies that make use of
autologous stem cells that are less thanminimallymanipulated
and not subject to regulatory scrutiny (Li et al., 2014). Then in
Part II I will argue for the need of an international support
structure that systematically addresses these problems. In this
regard, I will introduce five measures that may help to reduce
existing difficulties and to conduct international stem cell
trials in a more effective and cost-efficient way.is is an open access article under the CC BY license
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stem cell trialsA first challenge to the organization of multi-country stem
cell trials is the necessity to conduct long-term in-depth
research into the regulatory requirements of drug regulatory
authorities in multiple countries (OECD, 2011). Stem cell
therapies, as pointed out by Martell and colleagues ‘do not
neatly fit into current regulatory categories’, and the barriers
of translating stem cell-based approaches in functioning
therapies lie ‘in both technical and regulatory constraints’
(Martell et al., 2010: 451). Regulations for the clinical use of
stem cells are in many countries emerging only gradually and
far-reaching regulatory differences exist. For clinical investi-
gators and industry this diversified and rapidly changing
situation is confusing and poses significant organizational
difficulties (Rosemann, 2014a). What is required is a long-
term, reflective engagement with the review and approval
procedures that are handled by the drug regulatory authorities
in the countries in which a trial is conducted. In order to
develop study protocols that are compliant with the demands
of multiple regulatory agencies, gaps between jurisdictional
frameworks must be identified at an early stage of the clinical
translation process. This is a difficult task that takes time and
may be complicated by language barriers, insufficiently defined
regulatory procedures, cultural differences and disparities in
the enforcement of regulatory protocols (Ravinetto et al.,
2013). It is complicated, furthermore, because the regulatory
issues that are associated with the development of autologous
stem cell therapies (Hourd et al. 2014) do in important respects
differ from the characteristics that need to be taken into
account in the context of clinical trials with pluripotent stem
cells (Andrews et al., 2014).
A second challenge is that the interaction with medical
authorities in multiple countries is resulting in a very high level
of organizational complexity (Minisman et al., 2012). To file
applications at multiple drug regulatory agencies is a time, cost
and labor-intensive process that requires specially trained staff
and a well-functioning administrative infrastructure (Rosemann,
2014b). While for industry-sponsored trials this is not necessarily
a problem, for academic research groups and small-to-mid size
biotech companies (which at present are the main sponsors of
clinical stem cell trials) these resources are often not available
and difficult to acquire (Keirstead, 2012).
A third type of challenge are time delays, increased
costs and uncertainties that arise from non-existent or
still emerging regulatory procedures in some countries. In
China, for instance, where effective regulatory procedures
for the clinical testing of stem cell-based therapeutic ap-
proaches have until 2012 been non-existent, the China Food
and Drug Administration (CFDA) has repeatedly refused to
accept incoming investigational new drug (IND) applications
for stem cell-based products (Rosemann, 2013). Such unre-
solved regulatory issues can cause long-drawn-out delays and
additional costs to the sponsors of clinical stem cell trials, and
result in the need to apply for regulatory approval in another
country where regulatory procedures are clearer, and to
conduct the trial there (Bhagavati, 2014). But unresolved
regulatory issues and the potential for sudden regulatory
changes exist also in countries with highly developed regulatory
frameworks. Noteworthy is, in particular, the ongoing debateon who should regulate autologous stem cell interventions
(Zarzeczny et al., 2014). In the USA, for instance, think tanks
are using the case of autologous stem cells in order to promote
broader deregulation and several companies and professional
societies (most prominently the ICMS) have argued that
‘autologous cell products should be treated as part of medical
practice and thus not subjected to marketing approval’ (Bianco
and Sipp, 2014). These calls have resulted in a bill for the
Freedom of Choice Act that was put forward to the US congress
in April 2014. According to this bill investigational stem cell
technologies could be sold to terminally ill patients, outside of
the control of the US Food and Drug Administration (FDA)
(Morgan, 2014). Similar developments can also be reported
from other highly regulated countries. Australia, for instance,
has exempted autologous stem cells from the review proce-
dures of its drug regulatory agency (Tuch andWall, 2014) and in
Italy the use of autologous mesenchymal stem cells has been
taken out of the jurisdiction of the Italian Medicine's Agency in
2013 (Berger et al., 2014). These developments are likely to
influence regulations in other countries (Bianco and Sipp, 2014).
Most importantly, however, the jurisdictional variation in
regulatory frameworks and the prospect of ongoing policy
changes make the implementation of multi-country stem cell
trials more difficult and increase the risk of organizational
complications, unexpected or misplaced investments and time
delays.
A fourth challenge is that the high level of regulatory
variation across countries necessitates far-reaching forms of
scientific self-governance, training and procedural adjustments
in participating clinical trial sites (Rosemann, 2014b). A central
reason for this is, that the existence of regulatory differences
between national jurisdictions is reflected in contrasts of
clinical research practices and methodologies, at the level
of local medical institutions. In many countries, moreover,
knowledge on the conduct of systematized controlled stem
cells trials is often limited among clinical researchers (Li et
al., 2014). These disparities between and also within local
hospitals form a clear threat to the scientific integrity of
international stem cell trials (OECD, 2011). As a result,
intensive forms of staff training and adjustments of local
clinical research practices are necessary, so that standardized
research protocols can be implemented (Ravinetto et al.,
2013). Standardization requires, furthermore, the implemen-
tation of reliable monitoring and control infrastructures.
For academic investigators and small-to-mid size companies
the performances of these tasks pose a significant organiza-
tional and financial burden (Keirstead, 2012). Unless sufficient
funding for these forms of education and scientific self-
governance is acquired, multi-center international stem cell
trials cannot be conducted.The need for an international support structure
The International Society of Stem Cell Research (ISSCR) has in
2010 called for the need to harmonize regulations for the
clinical translation and commercialization of stem cell-based
products and therapies (Martell et al., 2010). However, in
2014 the global regulatory landscape for clinical stem cell
research remains as diverse as before. This situation continues
to pose problems to the organization of transnational stem cell
trials. What is needed in order to improve this situation is
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which the organizational challenges of multi-country stem
cell trials can be systematically addressed. International
bodies such as the ISSCR or the International Stem Cell
Forum have until now focused primarily on the development
of guidelines, best practice standards and various types of
recommendation. These documents have concentrated on
crucial aspects of the clinical translation process, including
the collection, derivation, storage and clinical application of
stem cells, as well as intellectual property rights, commercial-
ization, industry engagement and ethical issues of stem cell
research (Isasi, 2012). However, a support structure that
specifically addresses the regulatory and organizational chal-
lenges of multi-country stem cell trials has so far not yet been
developed. Such a scheme could encompass five elements:1. The development of a web-based databank that provides
detailed information on regulatory requirements and pro-
cedures for clinical stem cell research and marketing
approval in a large number of countries.
This repository could provide a detailed overview of re-
sponsible government units, key contacts, as well as reg-
ulatory documents and websites. Regulatory procedures
and manuals on how to apply for and conduct stem cell
clinical trials in different countries could be introduced in
detail. This databank could work with a computerized
system that explains differences between the regulatory
requirement of specific countries and regions, and that
helps to clarify what kind of tasks clinical trial sponsors will
have to perform to balance out these regulatory gaps. In
order to be valuable, such a database would have to
be nuanced for different cell types and manufacturing
standards. It would also have to provide information for
the regulation of combination therapies (such as cell
therapy-drug or cell therapy-device) where different reg-
ulatory pathways are required for each element.
2. The establishment of an international task force that identifies
the central challenges to multi-country stem cell trials.
This task force could consist of researchers and sponsors with
experience in the organization of multi-country trials. It
should strive for the identification of the key challenges for
the clinical translation of stem cell-based therapies in the
context of international projects. Such a task force could
aim, furthermore, for the development of solution strategies
through which international stem cell trials can be conduct-
ed in a more time and cost efficient way. These measures
could include, for example, information packages for
sponsors and clinical investigators, as well as tools for staff
training, project management and data collection. Such a
task force could be initiated by the ISSCR, the International
Stem Cell Forum (ISCF), or another international society such
as the International Society of Cellular Therapies (ISCT).
3. The creation of an interactive online education and
discussion platform.
The establishment of an interactive education and discus-
sion platform would allow for the sharing of criticalinformation and experiences of clinical trial sponsors and
investigators. Scientists or sponsors who plan to conduct
international stem cell trials can learn in this way from the
experiences of other researchers, andmake practice-based
assessments of the tasks, costs, timeframes and challenges
that may lie ahead of them. Such knowledge could also
help to make well-informed budgetary estimations, and to
gain access to other useful information such as information
about insurance schemes, the implementation of project-
internal monitoring systems, and ethics committee ap-
proval (Ravinetto et al., 2013).
4. Raise awareness of the challenges of multi-country stem
cell trials among public, private and charitable funding
bodies.
To facilitate international collaborations in the stem cell
field, it will be important to create an awareness of the
challenges of multi-country stem cell trials among public,
private and charitable funding bodies. To develop an
understanding of these problems it will be crucial to
prevent unrealistic expectations, and to obtain additional
money that is required to tackle the challenges associated
with international stem cell trials. A first step into this
direction has been made by researchers at the University
of Alberta in Canada, together with colleagues from McGill
University, the University of British Columbia and the
London Regenerative Medicine Network (Bubela et al.,
2012). This group has founded the interactive online forum
‘Enabling Advanced Cell Technologies (EnACT)’ [http://
enactforum.org], that offers an interactive, moderated
discussion platform that aims to develop ‘solutions to key
non-science barriers’ to the clinical translation of cell and
stem cell-based treatment pathways (Bubela et al., 2012).
The EnACT website features twelve thematic areas where
barriers to translational stem cell research emerge. How-
ever, the challenges for the organization of multi-country
clinical trial collaborations are not discussed on the forum.
Moreover, online forumsmay not be the best way to identify
and/or raise awareness of the challenges of international
stem cell trials. The organization of a series of workshops
and publications that could be organized by the ISSCR, the
ISCF, the ISCT or another professional organization promises
to be a more efficient method. Ideally, such workshops
would involve representatives from public as well as
charitable funding bodies, the industry and drug regulatory
agencies from multiple countries.
5. Promote forms of regulatory harmonization and lobby for
better communication between drug regulatory authorities.
A final field of activity would be the promotion of forms
or regulatory harmonization or at least, to lobby for better
communication between drug regulatory authorities, so that
some of the challenges regarding multi-country stem cell
trials can be prevented or reduced. Harmonization, as
recently pointed out in a position paper of the US FDA's
Office of Cellular, Tissue, and Gene Therapies, does not
necessarily imply the production of internationally
shared consensus guidelines (as in case of the ICH-GCP
standards). Harmonization can refer too to the partial
convergence of regulatory perspectives—but based on
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and guidelines (Arcidiacono et al., 2012). In light of the
current level of regulatory divergence in the clinical stem
cell field, it is questionable whether such a convergence
perspective could really be achieved. Be this as it may,
considering the existing challenges for the performance of
international stem cell trials, the move toward a more
coherent and predictable international regulatory land-
scape would clearly be advantageous.Conclusions
While there is little doubt that the introduction of such an
international support structure for multi-country stem cell
trials would be of great value, its feasibility must be viewed
from the perspective of possible sponsors. Considering the
high costs of clinical translation it is to be expected that
the greater part of Phase III trials will involve commercial
sponsors. A newly devised support structure, therefore,
must be of use to both academic investigators and corporate
sponsors. Ideally, representatives of both groups will be
involved in the design of these measures. It is not unlikely
though, that commercial sponsors may prefer to undertake
their own work into the regulatory barriers of international
stem cell trials, for instance by external regulatory affairs
consultants that help companies to navigate and identify
existing challenges. For fear of competition these corpora-
tions may not be willing or able to share this information
through online forums, publications or other means. At
present, however, the majority of clinical trials in the stem
cell field are either investigator-initiated or trials that are
organized by small to mid-size biotech companies, often
startups that operate under high risks. The financial means
of both of these groups are usually limited. Moreover the
time and organizational capacities—especially of academic
investigators—are highly restricted. For these groups a support
structure in which many of the question and practical
challenges that emerge in the context of multi-country stem
cell trials are discussed and anticipated will allow to save
costs, time and facilitate realistic assessments and planning. A
problem is, of course, that such initiatives are likely to be
expensive. The organization of such a support structure should
best lie in the hands of an international professional society
such as the International Society for Stem Cell Research or the
International Society of Cellular Therapies, which are large
scale organizations that represent large numbers of re-
searchers in many countries and that also cater the interests
of the industry. Alternatively, the International Stem Cell
Forum—which brings together some of the main public funding
bodies for stem cell research around the world—would be a
suitable umbrella organization for such an initiative. These
organizations are firmly grounded into the international
scientific community and have a high level of credibility.
Most importantly, they are most likely to reach a large number
of interested stakeholders and it also is in the interest of these
institutions to provide up-to-date information, to stimulate
participation and to disseminate findings from such an ini-
tiative. These large international organizations are also in the
best position to attract the funding for such a transnational
support structure, and to provide an apposite organizational
platform. Considering the high expenses and financial risks ofmulti-country stem cell trials and the potential for regulatory
misassessments and long-drawn-out delays, the money for
such an international support structure seems well invested.Acknowledgments
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